Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CENKOS SECURITIES PLC. We currently have 1 research reports from 1 professional analysts.
|23Mar17 10:29||RNS||Form 8.5 (EPT/NON-RI)|
|23Mar17 10:14||RNS||Form 8.3 - BowLeven Plc|
|17Mar17 11:16||RNS||Form 8.5 (EPT/NON-RI)|
|16Mar17 10:51||RNS||Form 8.5 (EPT/NON-RI)|
|15Mar17 10:08||RNS||Form 8.5 (EPT/NON-RI)|
|14Mar17 09:32||RNS||Form 8.5 (EPT/NON-RI)|
|10Mar17 10:17||RNS||Form 8.5 (EPT/NON-RI)|
Frequency of research reports
Research reports on
CENKOS SECURITIES PLC
CENKOS SECURITIES PLC
Transparent, entrepreneurial business model
26 May 16
Cenkos (CNKS) is a specialist institutional stockbroker with a consistent track record of profitability since its formation. Its entrepreneurial approach has helped attract an expanding client list and win mandates for substantial transactions, including the fund raise of over £1bn for BCA last year. The level of profit is subject to market fluctuations but the current valuation appears to reflect cautious assumptions given the group’s historical performance and attractive yield.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.